CLVS Stock Recent News

Investors were cheered by news of a freshly signed supply deal.

CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis.

After a massive surge in its share price recently, Clovis Oncology has started to reverse course.

Clovis Oncology has recently been on a winning streak of clinical data and corporate updates. As a result, the share price has rocketed off its 52-week lows. The company's theranostic FAP was able to show some efficacy in its Phase I trial. This validated the company's efforts to develop these programs.

Biotech stocks are back in favor as some risk-on activity permeates the broader market. Clovis Oncology (CLVS) shares spiked from under 50 cents to above $3 recently as news about its key drugs stirs up bullish fervor.

Clovis Oncology is skyrocketing after being flagged as a top gamma squeeze candidate. Here's why investors should be watching CLVS stock.

Clovis' (CLVS) shareholders decided to reject a proposal for a reverse split of CLVS stock. Clovis' shares appear to be rising on the news.

The company might have vanquished delisting concerns with its surge.

A key label expansion for the company's ovarian cancer drug could take longer than expected.

Clovis (CLVS) stock is on investors' radars as its shareholder meeting is resuming today. The company is seeking approval for a reverse split.